Orthopedic Biomaterials Market Size, Share and COVID-19 Impact Analysis | Europe | 2022-2028 | MedSuite | Includes: Bone Graft Substitutes, Orthopedic Growth Factors, and 3 more

  • Year: 2022
  • Scope: 10 Years
  • Region: Europe
  • Pages: 421
  • Published Date: 05/20/2022
  • Type: MedSuite

Product Description

The total European orthopedic biomaterials market is growing at a rate of 2%, which will take the 2021 market value of €550 million up to €632 million by 2028.

The full report suite on the European market for orthopedic biomaterials includes bone graft substitutes, which are represented by allografts, demineralized bone matrix (DBM) and synthetic bone grafts. The report also includes orthopedic growth factors, cell therapies, hyaluronic acid (HA) viscosupplementation and cartilage repair.

MARKET REPORT DATA TYPES INCLUDED

  • Unit Sales, Average Selling Prices, Market Value & Growth Trends
  • Forecasts Until 2028, and Historical Data to 2018
  • Market Drivers & Limiters for Each Segment
  • Competitive Analysis with Market Shares for Each Segment
  • Recent Mergers & Acquisitions
  • Procedure Volumes
  • Company Profiles, Product Portfolios and SWOT for Top Competitors
  • COVID-19 Impact Analysis

EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET TRENDSEuropean orthobiologics market

Demographic factors continue to be the largest driver within the orthopedic biomaterials market in Europe. This is primarily due to the growing elderly population, which is correlated to the incidence of osteoarthritis, osteoporosis, osteomalacia, rheumatoid arthritis and other bone diseases. As the aging population in Europe is growing alongside the majority of baby boomers reaching retirement age, the demand for bone graft substitutes will also increase. A lower level of physical activity is more common among older adults.

EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET SHARE INSIGHTS

Overall, within the European orthopedic biomaterials market there are two dominant competitors: Fidia and Medtronic.Top European orthopedic biomaterials leadersIn 2021, Fidia retained its spot as the leader within the European orthopedic biomaterials market. This is due to its orthopedic HA viscosupplementation products, Hyalubrix® and Hyalgan®, which maintained a strong presence in the market.

MARKET SEGMENTATION SUMMARY

You can view all these included reports and segmentation here:

  • Bone Graft Substitutes Market – MedCore – Includes:
    • Allografts, demineralized bone matrices (DBM) and synthetic bone grafts substitutes
  • Orthopedic Growth Factor Market – MedCore – Includes:
    • Segments for spine and tibial fracture
  • Orthopedic Cell Therapy Market – MedCore – Includes:
    • Platelet-rich plasma and bone marrow concentration segments
  • Hyaluronic Acid Viscosupplementation Market – MedCore – Includes:
    • Single-injection, Two-injection, Three-Injection, and Five-Injection products
  • Orthopedic Cartilage Repair Market – MedCore — Includes:
    • Osteochondral allografts, meniscal allografts, ACI products and osteochondral autografts

Global Research Scope Summary

Report Attribute Details
Regions  Europe
Base Year  2021
Forecast  2022-2028
Historical Data  2018-2021
Quantitative Coverage  Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices.
Qualitative Coverage COVID-19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors,   Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease   Overviews.
Data Sources Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data,   Import & Export Data, iData Research Internal Database.

 

FREE Sample Report

Table of Contents

TABLE of CONTENTS
List of Figures
List of Charts
executive summary
European Orthopedic Biomaterials Market Overview
Competitive Analysis
Market Trends
Market Developments
Procedure Numbers
Markets Included
Key Report Updates
Version History
research methodology
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
impact of covid-19 on THE European Orthopedic Biomaterials Market
2.1 Introduction
2.1.1 Treatable Population
2.2 Country Profiles
2.3 Analysis By Market Segment
2.3.1 Worst Case Scenario
2.3.2 Base Case Scenario
2.3.3 Best Case Scenario
Product Assessment
3.1 Introduction
3.2 Product Portfolios
3.2.1 Bone Graft Substitutes
3.2.2 Growth Factors
3.2.2.1.1 NELL-1 Bone Biologics
3.2.2.1.2 INFUSE® by Medtronic
3.2.2.1.3 OsteoAMP® by Bioventus Surgical
3.2.2.1.4 OP-1™ by Stryker / Olympus Biotech (delisted)
3.2.2.1.5 The Osteogrow Study
3.2.2.2 Other Products
3.2.2.2.1 AUGMENT® Bone Graft
3.2.2.2.2 Amplex® Osteobiologic Bone Graft Substitute
3.2.2.2.3 i-Factor™ Peptide Bone Matrix
3.2.3 Cellular Allografts (Stem Cell)
3.2.4 Cell Therapy
3.2.4.1 Platelet-Rich Plasma
3.2.4.2 Bone Marrow Aspirate Concentrate
3.2.5 Hyaluronic Acid Viscosupplementation (HAV)
3.2.6 Cartilage Repair
3.3 Regulatory Issues and Recalls
3.3.1 Bioventus
3.3.1.1 Bone Graft Substitute
3.3.2 Exactech
3.3.2.1 Bone Graft Substitute
3.3.3 Medtronic
3.3.3.1 Bone Graft Substitute
3.3.4 Sanofi
3.3.4.1 Hyaluronic Acid Viscosupplementation
3.3.5 Wright Medical (Stryker)
3.3.5.1 Bone Graft Substitute
3.3.6 Xtant
3.3.6.1 Bone Graft Substitute
3.3.7 Zimmer Biomet
3.3.7.1 Growth Factor
3.4 Clinical Trials
3.4.1 Arthrex
3.4.1.1 Bone Graft Substitute
3.4.2 DePuy Synthes
3.4.2.1 Cellular Allograft
3.4.3 RTI Surgical
3.4.3.1 Bone Graft Substitute
3.4.4 Stryker
3.4.4.1 Bone Graft Substitute
3.4.5 Others
3.4.5.1 Bone Graft Substitute
3.4.5.2 Growth Factor
3.4.5.3 Cellular Allograft
3.4.5.4 Cell Therapy
3.4.5.5 Hyaluronic Acid Viscosupplementation
3.4.5.6 Cartilage Repair
European Orthopedic Biomaterials Market Overview
4.1 Introduction
4.2 Currency Exchange Rate
4.3 Market Overview & Trend Analysis
4.4 Drivers and Limiters
4.4.1 Market Drivers
4.4.2 Market Limiters
4.5 Competitive Market Share Analysis
4.6 Mergers and Acquisitions
4.7 Company Profiles
4.7.1 Arthrex
4.7.2 Bioventus
4.7.3 DePuy Synthes
4.7.4 Ferring Pharmaceuticals
4.7.5 Fidia Farmaceutici
4.7.6 Harvest Technologies (Terumo BCT)
4.7.7 Medtronic
4.7.8 Musculoskeletal Transplant Foundation (MTF)
4.7.9 NuVasive
4.7.10 Orthofix
4.7.11 RTI Surgical
4.7.12 Sanofi
4.7.13 Stryker
4.7.14 Vericel Corporation
4.7.15 Zimmer Biomet
4.8 SWOT Analysis
4.8.1 Arthrex
4.8.2 Bioventus
4.8.3 DePuy Synthes
4.8.4 Ferring Pharmaceuticals
4.8.5 Fidia Farmaceutici
4.8.6 Harvest Technologies (Terumo BCT)
4.8.7 Medtronic
4.8.8 Musculoskeletal Transplant Foundation (MTF)
4.8.9 NuVasive
4.8.10 Orthofix
4.8.11 RTI Surgical
4.8.12 Sanofi
4.8.13 Stryker
4.8.14 Vericel
4.8.15 Zimmer Biomet
Country Profiles
5.1 Introduction
5.1.1 GDP Per Capita
5.1.2 Price Index
5.2 Germany
5.3 France
5.4 United Kingdom
5.5 Italy
5.6 Spain
5.7 Benelux
5.8 Scandinavia
5.9 Austria
5.10 Switzerland
5.11 Portugal
Procedure Numbers
6.1 Introduction
6.2 Procedures
6.2.1 Orthopedic Bone Grafting Procedures
6.2.1.1 Orthopedic Bone Grafting Procedures by Material
6.2.1.2 Orthopedic Bone Grafting Procedures by Indication
6.2.1.2.1 Average Units Used per Procedure by Indication
6.2.1.3 Allograft Procedures by Indication
6.2.1.4 DBM Procedures by Indication
6.2.1.5 Synthetic Procedures by Indication
6.2.1.6 Orthopedic Bone Grafting Procedures by Care Setting
6.2.2 Orthopedic Growth Factor Procedures
6.2.2.1 Orthopedic Growth Factor Procedures by Indication
6.2.2.2 Orthopedic Growth Factor Procedures by Care Setting
6.2.3 Orthopedic Cell Therapy Procedures
6.2.3.1 Orthopedic Cell Therapy Procedures by Material Type
6.2.3.2 Platelet-Rich Plasma Procedures
6.2.3.3 Bone Marrow Aspirate Concentrate Procedures
6.2.3.1 Orthopedic Cell Therapy Procedures by Care Setting
6.2.4 Hyaluronic Acid Viscosupplementation Procedures
6.2.4.1 Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle
6.2.4.1 Hyaluronic Acid Viscosupplementation Procedures by Care Setting
6.2.5 Orthopedic Cartilage Repair Procedures
6.2.5.1 Orthopedic Cartilage Repair Procedures by Type
6.2.5.2 Orthopedic Cartilage Repair Procedures by Care Setting
orthopedic Bone Graft Substitute Market
7.1 Introduction
7.2 Market Overview
7.3 Market Analysis and Forecast
7.3.1 Total Bone Graft Substitute Market
7.3.2 Allograft Bone Graft Substitute Market
7.3.3 Demineralized Bone Matrix Bone Graft Substitute Market
7.3.4 Synthetic Bone Graft Substitute Market
7.4 Unit Analysis
7.4.1 Total Bone Graft Substitute Unit Analysis
7.4.2 Allograft Bone Graft Substitute Unit Analysis
7.4.2.1 Allograft Bone Graft Substitute Units Sold by Indication
7.4.2.1.1 Spine Allograft Bone Graft Substitute Units Sold by Anatomy
7.4.2.1.2 Trauma Allograft Bone Graft Substitute Units Sold by Anatomy
7.4.2.1.3 Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold by Anatomy
7.4.2.1.4 Foot Reconstruction Allograft Bone Graft Substitute Units Sold
7.4.2.1.5 Craniomaxillofacial Allograft Bone Graft Substitute Units Sold
7.4.2.1.6 Oncology Allograft Bone Graft Substitute Units Sold
7.4.3 Demineralized Bone Matrix Allograft Unit Analysis
7.4.3.1 Demineralized Bone Matrix Allograft Units Sold by Indication
7.4.3.1.1 Spine Demineralized Bone Matrix Allograft Units Sold by Anatomy
7.4.3.1.2 Trauma Demineralized Bone Matrix Allograft Units Sold by Anatomy
7.4.3.1.3 Craniomaxillofacial Demineralized Bone Matrix Allograft Units Sold
7.4.4 Synthetic Bone Graft Substitute Unit Analysis
7.4.4.1 Synthetic Bone Graft Substitute Units Sold by Indication
7.4.4.1.1 Spine Synthetic Bone Graft Substitute Units Sold by Anatomy
7.4.4.1.2 Trauma Synthetic Bone Graft Substitute Units Sold by Anatomy
7.4.4.1.3 Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold by Anatomy
7.4.4.1.4 Foot Reconstruction Synthetic Bone Graft Substitute Units Sold
7.4.4.1.5 Craniomaxillofacial Synthetic Bone Graft Substitute Units Sold
7.4.4.1.6 Oncology Synthetic Bone Graft Substitute Units Sold
7.5 Drivers and Limiters
7.5.1 Market Drivers
7.5.2 Market Limiters
7.6 Competitive Market Share Analysis
ORthopedic Growth Factor Market
8.1 Introduction
8.1.1 BMP-2 (Medtronic)
8.2 Market Overview
8.3 Market Analysis and Forecast
8.3.1 Orthopedic Growth Factor Market
8.4 Unit Analysis
8.4.1 Spine Orthopedic Growth Factor Unit Analysis
8.4.2 Tibial Fracture Orthopedic Growth Factor Unit Analysis
8.5 Drivers and Limiters
8.5.1 Market Drivers
8.5.2 Market Limiters
8.6 Competitive Market Share Analysis
Orthopedic Cell Therapy Market
9.1 Introduction
9.2 Market Overview
9.3 Market Analysis and Forecast
9.3.1 Platelet-Rich Plasma Market
9.3.2 Bone Marrow Aspirate Concentrate Market
9.4 Unit Analysis
9.4.1 Platelet-Rich Plasma Units Sold by Indication
9.4.1.1 Soft Tissue Platelet-Rich Plasma Units Sold
9.4.1.2 Spine Platelet-Rich Plasma Units Sold
9.4.1.3 Cardiac Platelet-Rich Plasma Units Sold
9.4.1.4 Orthopedic Platelet-Rich Plasma Units Sold
9.4.1.5 Plastics Platelet-Rich Plasma Units Sold
9.4.2 Bone Marrow Aspirate Concentrate Units Sold by Indication
9.4.2.1 Spine Bone Marrow Aspirate Concentrate Units Sold
9.4.2.2 Soft Tissue Bone Marrow Aspirate Concentrate Units Sold
9.4.2.3 Trauma Bone Marrow Aspirate Concentrate Units Sold
9.4.2.4 Joint Reconstruction Bone Marrow Aspirate Concentrate Units Sold
9.5 Drivers and Limiters
9.5.1 Market Drivers
9.5.2 Market Limiters
9.6 Competitive Market Share Analysis
Hyaluronic Acid Viscosupplementation Market
10.1 Introduction
10.1.1 Benefits of Viscosupplementation
10.1.2 Synovial Fluid
10.1.3 Product Types
10.2 Market Overview
10.3 Market Analysis and Forecast
10.3.1 Total Hyaluronic Acid Viscosupplementation Market
10.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market
10.3.3 Two-Injection Hyaluronic Acid Viscosupplementation Market
10.3.4 Three-Injection Hyaluronic Acid Viscosupplementation Market
10.3.5 Five-Injection Hyaluronic Acid Viscosupplementation Market
10.4 Drivers and Limiters
10.4.1 Market Drivers
10.4.2 Market Limiters
10.5 Competitive Market Share Analysis
Orthopedic Cartilage Repair Market
11.1 Introduction
11.1.1 Anatomy
11.1.2 Methods for Cartilage Repair
11.1.2.1 Osteochondral Allograft Transfer
11.1.2.2 Autologous Chondrocyte Implantation (ACI)
11.1.2.3 Meniscal Allograft Transplantation
11.1.2.4 Osteochondral Autograft
11.2 Market Overview
11.3 Market Analysis and Forecast
11.3.1 Osteochondral Allograft Market
11.3.2 Meniscal Allograft Market
11.3.3 Autologous Chondrocyte Implantation Market
11.3.4 Osteochondral Autograft Market
11.4 Drivers and Limiters
11.4.1 Market Drivers
11.4.2 Market Limiters
11.5 Competitive Market Share Analysis
Abbreviations

Companies Included:

·         Adistem ·         DePuy Synthes
·         Alphatec ·         Documedica
·         Anika Therapeutics ·         Exactech
·         Arthrex ·         Ferring
·         Baxter ·         Fidia
·         BioCell ·         Finceramica
·         Biocomposites ·         Geistlich
·         Bioiberica ·         Harvest (Terumo)
·         Biomatlante ·         IBSA Pharma
·         Bioventus ·         Integra LifeSciences
·         Bonalive ·         Isto
·         Cerapedics ·         Kuros
·         CO.DON ·         LCA Pharmaceuticals
·         CONMED ·         Medtronic
·         Croma-Pharma ·         NovaBone
·         Curasan ·         Nuo Therapeutics

List of Charts

Chart 1‑1: Orthopedic Biomaterials Market by Segment, Europe, 2021 – 2028
Chart 1‑2: Orthopedic Biomaterials Market Overview, Europe, 2021 & 2028
Chart 2‑1: Multi-Scenario Orthopedic Biomaterials Market Forecast, Europe, 2018 – 2028 (€M)
Chart 4‑1: Orthopedic Biomaterials Market by Segment, Europe, 2018 – 2028
Chart 4‑2: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2021
Chart 5‑1: Country Profile, Germany, 2021
Chart 5‑2: Country Profile, France, 2021
Chart 5‑3: Country Profile, United Kingdom, 2021
Chart 5‑4: Country Profile, Italy, 2021
Chart 5‑5: Country Profile, Spain, 2021
Chart 5‑6: Country Profile, Benelux, 2021
Chart 5‑7: Country Profile, Scandinavia, 2021
Chart 5‑8: Country Profile, Austria, 2021
Chart 5‑9: Country Profile, Switzerland, 2021
Chart 5‑10: Country Profile, Portugal, 2021
Chart 7‑1: Bone Graft Substitute Market by Segment, Europe, 2018 – 2028
Chart 7‑2: Leading Competitors, Orthopedic Bone Graft Substitute Market, Europe, 2021
Chart 9‑1: Orthopedic Cell Therapy Market by Segment, Europe, 2018 – 2028
Chart 9‑2: Leading Competitors, Orthopedic Cell Therapy Market, Europe, 2021
Chart 10‑1: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2018 – 2028
Chart 10‑2: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Europe, 2021
Chart 11‑1: Orthopedic Cartilage Repair Market by Segment, Europe, 2018 – 2028
Chart 11‑2: Leading Competitors, Orthopedic Cartilage Repair Market, Europe, 2021

List of Figures

Figure 1‑1: Orthopedic Biomaterials Market Share Ranking by Segment, Europe, 2021
Figure 1‑2: Companies Researched in this Report (1 of 2)
Figure 1‑3: Companies Researched in this Report (2 of 2)
Figure 1‑4: Factors Impacting the Orthopedic Biomaterials Market by Segment, Europe (1 of 2)
Figure 1‑5: Factors Impacting the Orthopedic Biomaterials Market by Segment, Europe (2 of 2)
Figure 1‑6: Recent Events in the Orthopedic Biomaterials Market, Europe, 2018 – 2021
Figure 1‑7: Orthopedic Biomaterials Procedures Covered, Europe (1 of 2)
Figure 1‑8: Orthopedic Biomaterials Procedures Covered, Europe (2 of 2)
Figure 1‑9: Orthopedic Biomaterials Markets Covered, Europe (1 of 2)
Figure 1‑10: Orthopedic Biomaterials Markets Covered, Europe  (2 of 2)
Figure 1‑11: Key Report Updates (1 of 2)
Figure 1‑12: Key Report Updates (2 of 2)
Figure 1‑13: Version History
Figure 2‑1: Orthopedic Biomaterials Market by Segment, Worst Case Scenario, Europe, 2018 – 2028 (€M)
Figure 2‑2: Orthopedic Biomaterials Market by Segment, Base Case Scenario, Europe, 2018 – 2028 (€M)
Figure 2‑3: Orthopedic Biomaterials Market by Segment, Best Case Scenario, Europe, 2018 – 2028 (€M)
Figure 3‑1: Bone Graft Substitutes Products by Company (1 of 4)
Figure 3‑2: Bone Graft Substitutes Products by Company (2 of 4)
Figure 3‑3: Bone Graft Substitutes Products by Company (3 of 4)
Figure 3‑4: Bone Graft Substitutes Products by Company (4 of 4)
Figure 3‑5: Growth Factor Products by Company
Figure 3‑6: Estimates of Funding for Stem Cell Research
Figure 3‑7: Cellular Allograft Products by Company
Figure 3‑8: Cell Therapy Products by Company
Figure 3‑9: Hyaluronic Acid Viscosupplementation by Products by Company
Figure 3‑10: Cartilage Repair Products by Company
Figure 3‑11: Class 2 Device Recall Bioactive Bone Graft Putty
Figure 3‑12: Class 2 Device Recall Opteform Allograft Disc
Figure 3‑13: Class 2 Device Recall INFUSE Bone Graft X SMALL KIT
Figure 3‑14: Class 2 Device Recall SynviscOne
Figure 3‑15: Class 2 Device Recall PROSTIM 10cc INJECTABLE
Figure 3‑16: Class 2 Device Recall OsteoSelect Demineralized Bone Matrix (DBM) Putty
Figure 3‑17: Class 1 Device Recall EBI Osteogen Implantable Bone Growth Stimulator
Figure 2-18: Demineralized Bone Matrix Rotator Cuff Study
Figure 2-19: ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis (ViviGen)
Figure 2-20: Clinical Outcomes Associated With the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease (ViviGen)
Figure 2-21: Prospective SPINE Registry (SPINE)
Figure 2-22: ACDF Using Structural Allograft vs. Tritanium C
Figure 2-23: Long-term Safety and Effectiveness of AUGMENT® Injectable Bone Graft Compared to Autologous Bone Graft
Figure 2-24: Rate of Bony Fusion Using NanoBone® Synthetic Bone Graft Versus Local Autologous Bone Graft. (BONE)
Figure 2-25: Novel Porous Bioceramic Material as a Bone Substitute
Figure 2-26: Evaluation of the Effectiveness of AMPLEX® Compared to Autogenous Bone Grafts
Figure 2-27: Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care
Figure 2-28: Bone Marrow Aspirate Concentrate Use in Hip Osteoarthritis (BMAC)
Figure 2-29: A Prospective Study of Clinical Outcomes Following a Single Intradiscal Injection of Bone Marrow Aspirate Concentrate (BMAC) for Single Level Discogenic Low Back Pain
Figure 2-30: Platelet-Rich Plasma (PRP) for Treatment of Symptomatic Lumbar Facet Syndrome of the Spine
Figure 2-31: Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis (BMAC)
Figure 2-32: The Effectiveness of Different Doses of Hyaluronic Acid Injections in Knee Osteoarthritis.
Figure 2-33: Osteochondral Allograft in the Surgical Treatment of Basal Joint Arthritis
Figure 2-34: Prospective Evaluation of ProChondrix CR for Repair of Articular Cartilage Defects on Femoral Condyle and Patella
Figure 2-35: Phase 2 Clinical Trial of CartiLife® in the United States
Figure 4‑1: Currency Exchange Rate, 2021
Figure 4‑2: Orthopedic Biomaterials Market by Segment, Europe, 2018 – 2028 (€M)
Figure 4‑3: Orthopedic Biomaterials Market by Segment, Europe, 2018 – 2028 (US$M)
Figure 4‑4: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2021 (1 of 2)
Figure 4‑5: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2021 (2 of 2)
Figure 4‑6: SWOT Analysis, Arthrex
Figure 4‑7: SWOT Analysis, Bioventus
Figure 4‑8: SWOT Analysis, DePuy Synthes
Figure 4‑9: SWOT Analysis, Ferring Pharmaceuticals
Figure 4‑10: SWOT Analysis, Fidia Farmaceutici
Figure 4‑11: SWOT Analysis, Harvest Technologies
Figure 4‑12: SWOT Analysis, Medtronic
Figure 4‑13: SWOT Analysis, MTF
Figure 4‑14: SWOT Analysis, NuVasive
Figure 4‑15: SWOT Analysis, Orthofix
Figure 4‑16: SWOT Analysis, RTI Surgical
Figure 4‑17: SWOT Analysis, Genzyme (Sanofi)
Figure 4‑18: SWOT Analysis, Stryker
Figure 4‑19: SWOT Analysis, Vericel Corporation
Figure 4‑20: SWOT Analysis, Zimmer Biomet
Figure 6‑1: Orthopedic Biomaterials Procedures by Segment, Europe, 2018 – 2028
Figure 6‑2: Orthopedic Biomaterials Procedures by Segment, Europe, 2018 – 2028
Figure 6‑3: Orthopedic Bone Grafting Procedures by Country, Europe, 2018 – 2028
Figure 6‑4: Orthopedic Bone Grafting Procedures by Material, Europe, 2018 – 2028
Figure 6‑5: Orthopedic Bone Grafting Procedures by Indication, Europe, 2018 – 2028 (1 of 2)
Figure 6‑6: Orthopedic Bone Grafting Procedures by Indication, Europe, 2018 – 2028 (2 of 2)
Figure 6‑7: Cervical Spine Procedures by Country, Europe, 2018 – 2028
Figure 6‑8: Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028
Figure 6‑9: Non-Union Trauma Procedures by Country, Europe, 2018 – 2028
Figure 6‑10: Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028
Figure 6‑11: Hip Procedures by Country, Europe, 2018 – 2028
Figure 6‑12: Knee Procedures by Country, Europe, 2018 – 2028
Figure 6‑13: Foot Procedures by Country, Europe, 2018 – 2028
Figure 6‑14: Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028
Figure 6‑15: Oncology Procedures by Country, Europe, 2018 – 2028
Figure 6‑16: Average Units Used per Procedure by Indication, Europe, 2018 – 2028
Figure 6‑17: Allograft Procedures by Country, Europe, 2018 – 2028
Figure 6‑18: Allograft Procedures by Indication, Europe, 2018 – 2028 (1 of 2)
Figure 6‑19: Allograft Procedures by Indication, Europe, 2018 – 2028 (2 of 2)
Figure 6‑20: Allograft Cervical Spine Procedures by Country, Europe, 2018 – 2028
Figure 6‑21: Allograft Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028
Figure 6‑22: Allograft Non-Union Trauma Procedures by Country, Europe, 2018 – 2028
Figure 6‑23: Allograft Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028
Figure 6‑24: Allograft Hip Procedures by Country, Europe, 2018 – 2028
Figure 6‑25: Allograft Knee Procedures by Country, Europe, 2018 – 2028
Figure 6‑26: Allograft Foot Procedures by Country, Europe, 2018 – 2028
Figure 6‑27: Allograft Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028
Figure 6‑28: Allograft Oncology Procedures by Country, Europe, 2018 – 2028
Figure 6‑29: DBM Procedures by Country, Europe, 2018 – 2028
Figure 6‑30: DBM Procedures by Indication, Europe, 2018 – 2028
Figure 6‑31: DBM Cervical Spine Procedures by Country, Europe, 2018 – 2028
Figure 6‑32: DBM Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028
Figure 6‑33: DBM Non-Union Trauma Procedures by Country, Europe, 2018 – 2028
Figure 6‑34: DBM Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028
Figure 6‑35: DBM Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028
Figure 6‑36: Synthetic Procedures by Country, Europe, 2018 – 2028
Figure 6‑37: Synthetic Procedures by Indication, Europe, 2018 – 2028 (1 of 2)
Figure 6‑38: Synthetic Procedures by Indication, Europe, 2018 – 2028 (2 of 2)
Figure 6‑39: Synthetic Cervical Spine Procedures by Country, Europe, 2018 – 2028
Figure 6‑40: Synthetic Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028
Figure 6‑41: Synthetic Non-Union Trauma Procedures by Country, Europe, 2018 – 2028
Figure 6‑42: Synthetic Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028
Figure 6‑43: Synthetic Hip Procedures by Country, Europe, 2018 – 2028
Figure 6‑44: Synthetic Knee Procedures by Country, Europe, 2018 – 2028
Figure 6‑45: Synthetic Foot Procedures by Country, Europe, 2018 – 2028
Figure 6‑46: Synthetic Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028
Figure 6‑47: Synthetic Oncology Procedures by Country, Europe, 2018 – 2028
Figure 6‑48: Orthopedic Bone Grafting Procedures by Care Setting, Europe, 2018 – 2028
Figure 6‑49: Orthopedic Growth Factor Procedures by Country, Europe, 2018 – 2028
Figure 6‑50: Orthopedic Growth Factor Procedures by Indication, Europe, 2018 – 2028
Figure 6‑51: Spine Growth Factor Procedures by Country, Europe, 2018 – 2028
Figure 6‑52: Trauma Growth Factor Procedures by Country, Europe, 2018 – 2028
Figure 6‑53: Orthopedic Growth Factor Procedures by Care Setting, Europe, 2018 – 2028
Figure 6‑54: Orthopedic Cell Therapy Procedures by Country, Europe, 2018 – 2028
Figure 6‑55: Orthopedic Cell Therapy Procedures by Material Type, Europe, 2018 – 2028
Figure 6‑56: Platelet-Rich Plasma Procedures by Country, Europe, 2018 – 2028
Figure 6‑57: Bone Marrow Aspirate Concentrate Procedures by Indication, Europe, 2018 – 2028
Figure 6‑58: Orthopedic Cell Therapy Procedures by Care Setting, Europe, 2018 – 2028
Figure 6‑59: Hyaluronic Acid Viscosupplementation Total Injections by Country, Europe, 2018 – 2028
Figure 6‑60: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Europe,  2018 – 2028 (1 of 2)
Figure 6‑61: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Europe,  2018 – 2028 (2 of 2)
Figure 6‑62: Single-Injection Cycles by Country, Europe, 2018 – 2028
Figure 6‑63: Two-Injection Cycles by Country, Europe, 2018 – 2028
Figure 6‑64: Three-Injection Cycles by Country, Europe, 2018 – 2028
Figure 6‑65: Five-Injection Cycles by Country, Europe, 2018 – 2028
Figure 6‑66: Hyaluronic Acid Viscosupplementation Procedures by Care Setting, Europe,  2018 – 2028
Figure 6‑67: Orthopedic Cartilage Repair Procedures by Type, Europe, 2018 – 2028 (1 of 2)
Figure 6‑68: Autologous Chondrocyte Implantation Procedures by Country, Europe, 2018 – 2028
Figure 6‑69: Orthopedic Cartilage Repair Procedures by Care Setting, Europe, 2018 – 2028
Figure 7‑1: Bone Graft Substitute Market by Segment, Europe, 2018 – 2028 (€M)
Figure 7‑2: Bone Graft Substitute Market by Segment, Europe, 2018 – 2028 (US$M)
Figure 7‑3: Total Bone Graft Substitute Market, Europe, 2018 – 2028
Figure 7‑4: Units Sold by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028
Figure 7‑5: Average Selling Price by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (€)
Figure 7‑6: Average Selling Price by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (US$)
Figure 7‑7: Market Value by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (€M)
Figure 7‑8: Market Value by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (US$M)
Figure 7‑9: Allograft Market, Europe, 2018 – 2028
Figure 7‑10: Units Sold by Country, Allograft Market, Europe, 2018 – 2028
Figure 7‑11: Average Selling Price by Country, Allograft Market, Europe, 2018 – 2028 (€)
Figure 7‑12: Average Selling Price by Country, Allograft Market, Europe, 2018 – 2028 (US$)
Figure 7‑13: Market Value by Country, Allograft Market, Europe, 2018 – 2028 (€M)
Figure 7‑14: Market Value by Country, Allograft Market, Europe, 2018 – 2028 (US$M)
Figure 7‑15: Demineralized Bone Matrix Market, Europe, 2018 – 2028
Figure 7‑16: Units Sold by Country, Demineralized Bone Matrix Market, Europe, 2018 – 2028
Figure 7‑17: Average Selling Price by Country, Demineralized Bone Matrix Market, Europe, 2018 – 2028 (€)
Figure 7‑18: Average Selling Price by Country, Total Demineralized Bone Matrix Market, Europe, 2018 – 2028 (US$)
Figure 7‑19: Market Value by Country, Total Demineralized Bone Matrix Market, Europe, 2018 – 2028 (€M)
Figure 7‑20: Market Value by Country, Total Demineralized Bone Matrix Market, Europe, 2018 – 2028 (US$M)
Figure 7‑21: Synthetic Market, Europe, 2018 – 2028
Figure 7‑22: Units Sold by Country, Synthetic Market, Europe, 2018 – 2028
Figure 7‑23: Average Selling Price by Country, Total Synthetic Market, Europe, 2018 – 2028 (€)
Figure 7‑24: Average Selling Price by Country, Total Synthetic Market, Europe, 2018 – 2028 (US$)
Figure 7‑25: Market Value by Country, Total Synthetic Market, Europe, 2018 – 2028 (€M)
Figure 7‑26: Market Value by Country, Total Synthetic Market, Europe, 2018 – 2028 (US$M)
Figure 7‑27: Total Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 (1 of 2)
Figure 7‑28: Total Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 (2 of 2)
Figure 7‑29: Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028
Figure 7‑30: Spine Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028
Figure 7‑31: Units Sold by Country, Cervical Spine Allograft Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑32: Units Sold by Country, Thoracolumbar Spine Allograft Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑33: Trauma Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028
Figure 7‑34: Units Sold by Country, Non-Union Trauma Allograft Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑35: Units Sold by Country, Fresh Fracture Trauma Allograft Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑36: Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold by Anatomy, Europe, 2018 – 2028
Figure 7‑37: Units Sold by Country, Hip Large Joint Reconstruction Allograft Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑38: Units Sold by Country, Knee Large Joint Reconstruction Allograft Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑39: Units Sold by Country, Foot Reconstruction Allograft Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑40: Units Sold by Country, Craniomaxillofacial Allograft Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑41: Units Sold by Country, Oncology Allograft Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑42: Demineralized Bone Matrix Allograft Units Sold by Indication, Europe, 2018 – 2028
Figure 7‑43: Spine Demineralized Bone Matrix Allograft Units Sold by Anatomy,  Europe, 2018 – 2028
Figure 7‑44: Units Sold by Country, Cervical Spine Demineralized Bone Matrix Allograft, Europe, 2018 – 2028
Figure 7‑45: Units Sold by Country, Thoracolumbar Spine Demineralized Bone Matrix Allograft, Europe, 2018 – 2028
Figure 7‑46: Trauma Demineralized Bone Matrix Allograft Units Sold by Anatomy,  Europe, 2018 – 2028
Figure 7‑47: Units Sold by Country, Non-Union Trauma Demineralized Bone Matrix Allograft, Europe, 2018 – 2028
Figure 7‑48: Units Sold by Country, Fresh Fracture Trauma Demineralized Bone Matrix Allograft, Europe, 2018 – 2028
Figure 7‑49: Units Sold by Country, Craniomaxillofacial Demineralized Bone Matrix Allograft, Europe, 2018 – 2028
Figure 7‑50: Synthetic Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028
Figure 7‑51: Spine Synthetic Bone Graft Substitute Units Sold by Anatomy, Europe, 2018 – 2028
Figure 7‑52: Units Sold by Country, Cervical Spine Synthetic Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑53: Units Sold by Country, Thoracolumbar Spine Synthetic Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑54: Trauma Synthetic Bone Graft Substitute Units Sold by Indication, Europe,  2018 – 2028
Figure 7‑55: Units Sold by Country, Non-Union Trauma Synthetic Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑56: Units Sold by Country, Fresh Fracture Trauma Synthetic Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑57: Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold by Anatomy, Europe, 2018 – 2028
Figure 7‑58: Units Sold by Country, Hip Large Joint Reconstruction Synthetic Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑59: Units Sold by Country, Knee Large Joint Reconstruction Synthetic Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑60: Units Sold by Country, Foot Reconstruction Synthetic Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑61: Units Sold by Country, Craniomaxillofacial Synthetic Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑62: Units Sold by Country, Oncology Synthetic Bone Graft Substitute, Europe, 2018 – 2028
Figure 7‑63: Leading Competitors by Country, Orthopedic Bone Graft Substitute Market, Europe, 2021
Figure 8‑1: Orthopedic Growth Factor Market by Segment, Europe, 2018 – 2028 (€M)
Figure 8‑2: Orthopedic Growth Factor Market by Segment, Europe, 2018 – 2028 (US$M)
Figure 8‑3: Orthopedic Growth Factor Market, Europe, 2018 – 2028
Figure 8‑4: Units Sold (5 cc) by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028
Figure 8‑5: Average Selling Price by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (€)
Figure 8‑6: Average Selling Price by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (US$)
Figure 8‑7: Market Value by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (€M)
Figure 8‑8: Market Value by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (US$M)
Figure 8‑9: Units Sold (5 cc) by Country, Spine Orthopedic Growth Factor Market, Europe, 2018 – 2028
Figure 8‑10: Units Sold (5 cc) by Country, Tibial Fracture Orthopedic Growth Factor Market, Europe, 2018 – 2028
Figure 8‑11: Leading Competitors by Country, Orthopedic Growth Factor Market, Europe, 2021
Figure 9‑1: Orthopedic Cell Therapy Market by Segment, Europe, 2018 – 2028 (€M)
Figure 9‑2: Orthopedic Cell Therapy Market by Segment, Europe, 2018 – 2028 (US$M)
Figure 9‑3: Platelet-Rich Plasma Market, Europe, 2018 – 2028
Figure 9‑4: Units Sold (10cc) by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028
Figure 9‑5: Average Selling Price by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (€)
Figure 9‑6: Average Selling Price by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (US$)
Figure 9‑7: Market Value by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (€M)
Figure 9‑8: Market Value by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (US$M)
Figure 9‑9: Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028
Figure 9‑10: Units Sold (10cc) by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028
Figure 9‑11: Average Selling Price by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (€)
Figure 9‑12: Average Selling Price by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (US$)
Figure 9‑13: Market Value by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (€M)
Figure 9‑14: Market Value by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (US$M)
Figure 9‑15: Units Sold by Country, Soft Tissue Platelet-Rich Plasma, Europe, 2018 – 2028
Figure 9‑16: Units Sold by Country, Spine Platelet-Rich Plasma, Europe, 2018 – 2028
Figure 9‑17: Units Sold by Country, Cardiac Platelet-Rich Plasma, Europe, 2018 – 2028
Figure 9‑18: Units Sold by Country, Orthopedic Platelet-Rich Plasma, Europe, 2018 – 2028
Figure 9‑19: Units Sold by Country, Plastics Platelet-Rich Plasma, Europe, 2018 – 2028
Figure 9‑20: Units Sold (10cc) by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028
Figure 9‑21: Units Sold (10cc) by Country, Soft Tissue Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028
Figure 9‑22: Units Sold (10cc) by Country, Trauma Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028
Figure 9‑23: Units Sold (10cc) by Country, Joint Reconstruction Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028
Figure 9‑24: Leading Competitors by Country, Orthopedic Cell Therapy Market, Europe, 2021
Figure 10‑1: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2018 – 2028 (€M)
Figure 10‑2: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2018 – 2028 (US$M)
Figure 10‑3: Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028
Figure 10‑4: Units Sold (Cycles) by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028
Figure 10‑5: Average Selling Price by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (€)
Figure 10‑6: Average Selling Price by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (US$)
Figure 10‑7: Market Value by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (€M)
Figure 10‑8: Market Value by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (US$M)
Figure 10‑9: Single-Injection Market, Europe, 2018 – 2028
Figure 10‑10: Units Sold (Cycles) by Country, Single-Injection Market, Europe, 2018 – 2028
Figure 10‑11: Average Selling Price by Country, Single-Injection Market, Europe, 2018 – 2028 (€)
Figure 10‑12: Average Selling Price by Country, Single-Injection Market, Europe, 2018 – 2028 (US$)
Figure 10‑13: Market Value by Country, Single-Injection Market, Europe, 2018 – 2028 (€M)
Figure 10‑14: Market Value by Country, Single-Injection Market, Europe, 2018 – 2028 (US$M)
Figure 10‑15: Two-Injection Market, Europe, 2018 – 2028
Figure 10‑16: Units Sold (Cycles) by Country, Two-Injection Market, Europe, 2018 – 2028
Figure 10‑17: Average Selling Price by Country, Two-Injection Market, Europe, 2018 – 2028 (€)
Figure 10‑18: Average Selling Price by Country, Two-Injection Market, Europe, 2018 – 2028 (US$)
Figure 10‑19: Market Value by Country, Two-Injection Market, Europe, 2018 – 2028 (€M)
Figure 10‑20: Market Value by Country, Two-Injection Market, Europe, 2018 – 2028 (US$M)
Figure 10‑21: Three-Injection Market, Europe, 2018 – 2028
Figure 10‑22: Units Sold (Cycles) by Country, Three-Injection Market, Europe, 2018 – 2028
Figure 10‑23: Average Selling Price by Country, Three-Injection Market, Europe, 2018 – 2028 (€)
Figure 10‑24: Average Selling Price by Country, Three-Injection Market, Europe, 2018 – 2028 (US$)
Figure 10‑25: Market Value by Country, Three-Injection Market, Europe, 2018 – 2028 (€M)
Figure 10‑26: Market Value by Country, Three-Injection Market, Europe, 2018 – 2028 (US$M)
Figure 10‑27: Five-Injection Market, Europe, 2018 – 2028
Figure 10‑28: Units Sold (Cycles) by Country, Five-Injection Market, Europe, 2018 – 2028
Figure 10‑29: Average Selling Price by Country, Five-Injection Market, Europe, 2018 – 2028 (€)
Figure 10‑30: Average Selling Price by Country, Five-Injection Market, Europe, 2018 – 2028 (US$)
Figure 10‑31: Market Value by Country, Five-Injection Market, Europe, 2018 – 2028 (€M)
Figure 10‑32: Market Value by Country, Five-Injection Market, Europe, 2018 – 2028 (US$M)
Figure 10‑33: Leading Competitors by Country, Hyaluronic Acid Viscosupplementation Market, Europe, 2021
Figure 11‑1: Orthopedic Cartilage Repair Market by Segment, Europe, 2018 – 2028 (€M)
Figure 11‑2: Orthopedic Cartilage Repair Market by Segment, Europe, 2018 – 2028 (US$M)
Figure 11‑3: Osteochondral Allograft Market, Europe, 2018 – 2028
Figure 11‑4: Meniscal Allograft Market, Europe, 2018 – 2028
Figure 11‑5: Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028
Figure 11‑6: Units Sold by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028
Figure 11‑7: Average Selling Price by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (€)
Figure 11‑8: Average Selling Price by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (US$)
Figure 11‑9: Market Value by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (€M)
Figure 11‑10: Market Value by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (US$M)
Figure 11‑11: Osteochondral Autograft Market, Europe, 2018 – 2028
Figure 11‑12: Leading Competitors, Orthopedic Cartilage Repair Market, Europe, 2021

iData’s 9-Step Research Methodology

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology

Explore Options

Report Summary

FREE

Select License Type

The European Orthopedic Biomaterials market report covers and includes the Bone Graft Substitutes Market, Orthopedic Growth Factor Market , Orthopedic Cell Therapy Market, Hyaluronic Acid Viscosupplementation Market, and the Orthopedic Cartilage Repair Market.

  • 2022
  • 10 Years
  • Europe
  • MedSuite
  • 421
  • 05/20/2022
0
    0
    Your Cart
    Your cart is emptyReturn to Report Library